Related references
Note: Only part of the references are listed.Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study
Werner Poewe et al.
JOURNAL OF PARKINSONS DISEASE (2021)
Active immunization with tau epitope in a mouse model of tauopathy induced strong antibody response together with improvement in short memory and pSer396-tau pathology
A. Joy-Amado et al.
NEUROBIOLOGY OF DISEASE (2020)
Advances and considerations in AD tau-targeted immunotherapy
Alice Bittar et al.
NEUROBIOLOGY OF DISEASE (2020)
The Challenge of Disease-Modifying Therapies in Parkinson's Disease: Role of CSF Biomarkers
Federico Paolini Paoletti et al.
BIOMOLECULES (2020)
Microglia clear neuron-released a-synuclein via selective autophagy and prevent neurodegeneration
Insup Choi et al.
NATURE COMMUNICATIONS (2020)
Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes
Adam S. Fleisher et al.
JAMA NEUROLOGY (2020)
Role of Alterations in Protein Kinase p38γ in the Pathogenesis of the Synaptic Pathology in Dementia With Lewy Bodies and α-Synuclein Transgenic Models
Michiyo Iba et al.
FRONTIERS IN NEUROSCIENCE (2020)
Tau immunotherapies: Lessons learned, current status and future considerations
L. A. Sandusky-Beltran et al.
NEUROPHARMACOLOGY (2020)
Immunotherapies for Aging-Related Neurodegenerative Diseases-Emerging Perspectives and New Targets
Somin Kwon et al.
NEUROTHERAPEUTICS (2020)
DNA vaccines: prime time is now
Ebony N. Gary et al.
CURRENT OPINION IN IMMUNOLOGY (2020)
Safety and immunogenicity of the α-synuclein active immunotherapeutic PDO1A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial
Dieter Volc et al.
LANCET NEUROLOGY (2020)
Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials
Irina Petrushina et al.
NEUROBIOLOGY OF DISEASE (2020)
Where and how alpha-synuclein pathology spreads in Parkinson's disease
Koichi Wakabayashi
NEUROPATHOLOGY (2020)
Emerging blood-based biomarkers for Alzheimer disease
Lynn M. Bekris et al.
CLEVELAND CLINIC JOURNAL OF MEDICINE (2020)
A Phase 1 Randomized Trial of Specific Activeα-SynucleinImmunotherapiesPD01AandPD03Ain Multiple System Atrophy
Wassilios G. Meissner et al.
MOVEMENT DISORDERS (2020)
Immunogenicity and Toxicity of Different Adjuvants Can Be Characterized by Profiling Lung Biomarker Genes After Nasal Immunization
Eita Sasaki et al.
FRONTIERS IN IMMUNOLOGY (2020)
Immunotherapy Targeting Neurodegenerative Proteinopathies: α-Synucleinopathies and Tauopathies
Junghwan Shin et al.
JOURNAL OF MOVEMENT DISORDERS (2020)
C-terminal -synuclein truncations are linked to cysteine cathepsin activity in Parkinson's disease
Ryan P. McGlinchey et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
How is alpha-synuclein cleared from the cell?
Leonidas Stefanis et al.
JOURNAL OF NEUROCHEMISTRY (2019)
Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer's disease
James A. R. Nicoll et al.
BRAIN (2019)
CSF and blood biomarkers for Parkinson's disease
Lucilla Parnetti et al.
LANCET NEUROLOGY (2019)
The Role of Antibodies and Their Receptors in Protection Against Ordered Protein Assembly in Neurodegeneration
Taxiarchis Katsinelos et al.
FRONTIERS IN IMMUNOLOGY (2019)
Understanding the pathogenesis of multiple system atrophy: state of the art and future perspectives
Giacomo Monzio Compagnoni et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2019)
A Comparison of Plasmid DNA and mRNA as Vaccine Technologies
Margaret A. Liu
VACCINES (2019)
A MuItiTEP platform-based epitope vaccine targeting the phosphatase activating domain (PAD) of tau: therapeutic efficacy in PS19 mice
Armine Hovakimyan et al.
SCIENTIFIC REPORTS (2019)
Engineering synucleinopathy-resistant human dopaminergic neurons by CRISPR-mediated deletion of the SNCA gene
Yixi Chen et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2019)
Sex differences in vaccine-induced humoral immunity
Stephanie Fischinger et al.
SEMINARS IN IMMUNOPATHOLOGY (2019)
Immunotherapy in Parkinson's disease: Current status and future directions
Diptaman Chatterjee et al.
NEUROBIOLOGY OF DISEASE (2019)
Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo
Darren J. Schofield et al.
NEUROBIOLOGY OF DISEASE (2019)
Testing a MultiTEP-based combination vaccine to reduce Aβ and tau pathology in Tau22/5xFAD bigenic mice
Hayk Davtyan et al.
ALZHEIMERS RESEARCH & THERAPY (2019)
Dale Schenk One Year Anniversary: Fighting to Preserve the Memories
Cassia Overk et al.
JOURNAL OF ALZHEIMERS DISEASE (2018)
Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations
Anthony E. Lang et al.
MOVEMENT DISORDERS (2018)
Sex differences in Alzheimer disease - the gateway to precision medicine
Maria Teresa Ferretti et al.
NATURE REVIEWS NEUROLOGY (2018)
Mechanisms of α-Synuclein Induced Synaptopathy in Parkinson's Disease
Jessika C. Bridi et al.
FRONTIERS IN NEUROSCIENCE (2018)
Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation
Changyoun Kim et al.
MOLECULAR NEURODEGENERATION (2018)
Alpha-synuclein and the prion hypothesis in Parkinson's disease
R. Melki
REVUE NEUROLOGIQUE (2018)
Sex Differences in Neuropathology and Cognitive Behavior in APP/PS1/tau Triple-Transgenic Mouse Model of Alzheimer's Disease
Jun-Ting Yang et al.
NEUROSCIENCE BULLETIN (2018)
The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease
Diana L. Price et al.
SCIENTIFIC REPORTS (2018)
Ten Years of Tau-Targeted Immunotherapy: The Path Walked and the Roads Ahead
Petr Novak et al.
FRONTIERS IN NEUROSCIENCE (2018)
Plasmid DNA vaccines: where are we now?
F. Ghaffarifar
DRUGS OF TODAY (2018)
Proteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson's disease model
Diptaman Chatterjee et al.
NPJ PARKINSONS DISEASE (2018)
Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency
Michael G. Agadjanyan et al.
MOLECULAR NEURODEGENERATION (2017)
MultiTEP platform-based DNA vaccines for alpha-synucleinopathies: preclinical evaluation of immunogenicity and therapeutic potency
Hayk Davtyan et al.
NEUROBIOLOGY OF AGING (2017)
Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy
Omar El-Agnaf et al.
NEUROBIOLOGY OF DISEASE (2017)
MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice
Hayk Davtyan et al.
VACCINE (2017)
Early synaptic dysfunction induced by α-synuclein in a rat model of Parkinson's disease
Jenny-Ann Phan et al.
SCIENTIFIC REPORTS (2017)
Tau passive immunization inhibits not only tau but also Aβ pathology
Chun-ling Dai et al.
ALZHEIMERS RESEARCH & THERAPY (2017)
The Synucleinopathies: Twenty Years On
Michel Goedert et al.
JOURNAL OF PARKINSONS DISEASE (2017)
Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy
Brian Spencer et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2017)
Immunotherapeutic Approaches Targeting Amyloid-beta, alpha-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders
Elvira Valera et al.
NEUROTHERAPEUTICS (2016)
How strong is the evidence that Parkinson's disease is a prion disorder?
Patrik Brundin et al.
CURRENT OPINION IN NEUROLOGY (2016)
Pathogenic mechanisms of prion protein, amyloid-β and α-synuclein misfolding: the prion concept and neurotoxicity of protein oligomers
Cathryn L. Ugalde et al.
JOURNAL OF NEUROCHEMISTRY (2016)
Exposure to bacterial endotoxin generates a distinct strain of α-synuclein fibril
Changyoun Kim et al.
SCIENTIFIC REPORTS (2016)
Alzheimer's disease AdvaxCpG-adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules
Hayk Davtyan et al.
SCIENTIFIC REPORTS (2016)
The Prion Hypothesis of Parkinson's Disease
Yaping Chu et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2015)
Naive T Cell Maintenance and Function in Human Aging
Joerg J. Goronzy et al.
JOURNAL OF IMMUNOLOGY (2015)
Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy
Markus Mandler et al.
MOLECULAR NEURODEGENERATION (2015)
Sex-based differences in immune function and responses to vaccination
Sabra L. Klein et al.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2015)
Antagonizing Neuronal Toll-like Receptor 2 Prevents Synucleinopathy by Activating Autophagy
Changyoun Kim et al.
CELL REPORTS (2015)
Passive Immunization with Phospho-Tau Antibodies Reduces Tau Pathology and Functional Deficits in Two Distinct Mouse Tauopathy Models
Sethu Sankaranarayanan et al.
PLOS ONE (2015)
Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials
Markus Mandler et al.
ACTA NEUROPATHOLOGICA (2014)
Epitope-based DNA vaccine for Alzheimer's disease: Translational study in macaques
Claire F. Evans et al.
ALZHEIMERS & DEMENTIA (2014)
The MultiTEP platform-based Alzheimer's disease epitope vaccine activates a broad repertoire of T helper cells in nonhuman primates
Hayk Davtyan et al.
ALZHEIMERS & DEMENTIA (2014)
Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo
Edward Rockenstein et al.
BRAIN (2014)
Reducing C-Terminal-Truncated Alpha-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson's Disease-Like Models
Dora Games et al.
JOURNAL OF NEUROSCIENCE (2014)
ESCRT-mediated Uptake and Degradation of Brain-targeted α-synuclein Single Chain Antibody Attenuates Neuronal Degeneration In Vivo
Brian Spencer et al.
MOLECULAR THERAPY (2014)
Immunogenicity of epitope vaccines targeting different B cell antigenic determinants of human α-synuclein: Feasibility study
Anahit Ghochikyan et al.
NEUROSCIENCE LETTERS (2014)
Axonopathy in an α-Synuclein Transgenic Model of Lewy Body Disease Is Associated with Extensive Accumulation of C-Terminal Truncated α-Synuclein
Dora Games et al.
AMERICAN JOURNAL OF PATHOLOGY (2013)
Time course and progression of wild type α-Synuclein accumulation in a transgenic mouse model
David Amschl et al.
BMC NEUROSCIENCE (2013)
PASSIVE IMMUNOTHERAPY FOR ALZHEIMER'S DISEASE: WHAT HAVE WE LEARNED, AND WHERE ARE WE HEADED?
P. S. Aisen et al.
JOURNAL OF NUTRITION HEALTH & AGING (2013)
Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo
Kiran Yanamandra et al.
NEURON (2013)
Immunotherapy for neurodegenerative diseases: Focus on α-synucleinopathies
Elvira Valera et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Refinement of a DNA based Alzheimer disease epitope vaccine in rabbits
Anahit Ghochikyan et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2013)
Antibody-Aided Clearance of Extracellular α-Synuclein Prevents Cell-to-Cell Aggregate Transmission
Eun-Jin Bae et al.
JOURNAL OF NEUROSCIENCE (2012)
Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts
Lisa Fellner et al.
ACTA NEUROPATHOLOGICA (2011)
Pathological roles of α-synuclein in neurological disorders (vol 10, pg 1015, 2011)
K. Vekrellis et al.
LANCET NEUROLOGY (2011)
Exogenous α-Synuclein Fibrils Induce Lewy Body Pathology Leading to Synaptic Dysfunction and Neuron Death
Laura A. Volpicelli-Daley et al.
NEURON (2011)
Vaccination for Parkinson's disease
A. Schneeberger et al.
PARKINSONISM & RELATED DISORDERS (2011)
Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease
Eliezer Masliah et al.
PLOS ONE (2011)
Pathological roles of α-synuclein in neurological disorders
Kostas Vekrellis et al.
LANCET NEUROLOGY (2011)
Papp-Lantos inclusions and the pathogenesis of multiple system atrophy: an update
Kurt A. Jellinger et al.
ACTA NEUROPATHOLOGICA (2010)
Therapeutic versus neuroinflammatory effects of passive immunization is dependent on Aβ/amyloid burden in a transgenic mouse model of Alzheimer's disease
S. Sakura Minami et al.
JOURNAL OF NEUROINFLAMMATION (2010)
Selective Molecular Alterations in the Autophagy Pathway in Patients with Lewy Body Disease and in Models of α-Synucleinopathy
Leslie Crews et al.
PLOS ONE (2010)
Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein
Paula Desplats et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Immunity, ageing and cancer
Evelyna Derhovanessian et al.
Immunity & Ageing (2008)
Transgenic animal models of neurodegenerative diseases and their application to treatment development
Edward Rockenstein et al.
ADVANCED DRUG DELIVERY REVIEWS (2007)
Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements
Ayodeji A. Asuni et al.
JOURNAL OF NEUROSCIENCE (2007)
Presynaptic α-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies
Michael L. Kramer et al.
JOURNAL OF NEUROSCIENCE (2007)
Mechanisms of Parkinson's disease linked to pathological α-synuclein:: New targets for drug discovery
Virginia M. -Y. Lee et al.
NEURON (2006)
Does levodopa slow or hasten the rate of progression of Parkinson's disease?
S Fahn
JOURNAL OF NEUROLOGY (2005)
Effects of α-synuclein immunization in a mouse model of Parkinson's disease
E Masliah et al.
NEURON (2005)
Differential neuropathological alterations in transgenic mice expressing α-synuclein from the platelet-derived growth factor and Thy-1 promoters
E Rockenstein et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2002)
Dopaminergic loss and inclusion body formation in α-synuclein mice:: Implications for neurodegenerative disorders
E Masliah et al.
SCIENCE (2000)
Share Paper
